Interleukin-32: its role in asthma and potential as a therapeutic agent.
Tong XinMo ChenLiwei DuanYanling XuPeng GaoPublished in: Respiratory research (2018)
Interleukin (IL)-32, also named natural killer cell transcript 4 (NK4), has increasingly been described as an immunoregulator that controls cell differentiation and cell death and is involved in the stimulation of anti-/pro-inflammatory cytokines. Abnormal presence of IL-32 has been repeatedly noticed during the pathogenesis of allergic, infectious, cancerous, and inflammatory diseases. Of particular note was the observation of the anti-inflammatory property of IL-32 in a murine ovalbumin model of allergic asthma. Compared to wild-type mice, IL-32γ transgenic mice show decreased levels of inflammatory cells, recruited eosinophils, and lymphocytes in bronchoalveolar lavage fluid in a mouse model of acute asthma. To date, the molecular mechanism underlying the role of IL-32 in asthma remains to be elucidated. This review aims to summarize recent advances in the pathophysiology of asthma and describe the links to IL-32. The possibilities of using IL-32 as an airway inflammation biomarker and an asthma therapeutic agent are also evaluated.
Keyphrases
- allergic rhinitis
- chronic obstructive pulmonary disease
- lung function
- cell death
- oxidative stress
- anti inflammatory
- wild type
- stem cells
- risk assessment
- air pollution
- induced apoptosis
- cell cycle arrest
- cystic fibrosis
- rna seq
- single cell
- bone marrow
- metabolic syndrome
- adipose tissue
- cell proliferation
- drug induced
- respiratory failure
- peripheral blood
- extracorporeal membrane oxygenation